Literature DB >> 21988888

A novel, patient-specific mathematical pathology approach for assessment of surgical volume: application to ductal carcinoma in situ of the breast.

Mary E Edgerton1, Yao-Li Chuang, Paul Macklin, Wei Yang, Elaine L Bearer, Vittorio Cristini.   

Abstract

We introduce a novel "mathematical pathology" approach, founded on a biophysical model, to identify robust patient-specific predictors of tumor growth useful in clinical practice to improve the accuracy of diagnosis/prognosis and intervention. In accordance with biological observations, our model simulates the diffusion-limited in situ tumors with a relatively short phase of fast initial growth, followed by a prolonged slow-growth phase where tumor size is constrained primarily by the relative weight of cell mitosis and death. The former phase may only last for a few months, so that at the time of diagnosis, we may assume that most tumors will have entered the phase where their size is changing slowly. Based on this prediction, we hypothesize that the volume of breast with ducts affected by in situ tumors at the time of diagnosis will be closely approximated by a model-derived mathematical function based on the ratio of tumor cell proliferation-to-apoptosis indices and on the extent of diffusion of cell nutrients (diffusion penetration length), which can be measured from immunohistochemical and morphometric analysis of patient histopathology specimens without the need for multiple-time measurements. We tested this idea in a retrospective study of 17 patients by staining breast tumor specimens containing ductal carcinoma in situ for mitosis with Ki-67 and for apoptosis with cleaved caspase-3 and counting cells positive for each marker. We also determined diffusion penetration by measuring the thickness of viable rims of tumor cells within ducts. Using the ensuing ratios, we applied the model to determine a predicted surgical volume or tumor size. We then corroborated our hypothesis by comparing the predicted size of each tumor based on our model with the actual size of the pathological specimen after tumor excision (R2 = 0.74-0.88). In addition, for the 17 cases studied, both histological grade and mammography were not found to correlate with tumor size (R2 = 0.08-0.47). We conclude that our mathematical pathology approach yields a high degree of accuracy in predicting the size of tumors based on the mitotic/apoptotic index and on diffusion penetration. By obtaining these ratios at the time of initial biopsy, pathologists can employ our model to predict the size of the tumor and thereby inform surgeons how much tissue to remove (surgical volume). We discuss how results from the model have implications concerning the current debate on recommendations for screening mammography, while the model itself may contribute to better planning of breast conservation surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21988888      PMCID: PMC3613121          DOI: 10.3233/ACP-2011-0019

Source DB:  PubMed          Journal:  Anal Cell Pathol (Amst)        ISSN: 2210-7177            Impact factor:   2.916


  26 in total

1.  Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies.

Authors:  Terisse A Brocato; Ursa Brown-Glaberman; Zhihui Wang; Reed G Selwyn; Colin M Wilson; Edward F Wyckoff; Lesley C Lomo; Jennifer L Saline; Anupama Hooda-Nehra; Renata Pasqualini; Wadih Arap; C Jeffrey Brinker; Vittorio Cristini
Journal:  JCI Insight       Date:  2019-03-05

Review 2.  Integrated PK-PD and agent-based modeling in oncology.

Authors:  Zhihui Wang; Joseph D Butner; Vittorio Cristini; Thomas S Deisboeck
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-01-15       Impact factor: 2.745

3.  A hybrid agent-based model of the developing mammary terminal end bud.

Authors:  Joseph D Butner; Yao-Li Chuang; Eman Simbawa; A S Al-Fhaid; S R Mahmoud; Vittorio Cristini; Zhihui Wang
Journal:  J Theor Biol       Date:  2016-07-28       Impact factor: 2.691

4.  Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression.

Authors:  Paul Macklin; Mary E Edgerton; Alastair M Thompson; Vittorio Cristini
Journal:  J Theor Biol       Date:  2012-02-09       Impact factor: 2.691

5.  Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Authors:  Eugene J Koay; Mark J Truty; Vittorio Cristini; Ryan M Thomas; Rong Chen; Deyali Chatterjee; Ya'an Kang; Priya R Bhosale; Eric P Tamm; Christopher H Crane; Milind Javle; Matthew H Katz; Vijaya N Gottumukkala; Marc A Rozner; Haifa Shen; Jeffery E Lee; Huamin Wang; Yuling Chen; William Plunkett; James L Abbruzzese; Robert A Wolff; Gauri R Varadhachary; Mauro Ferrari; Jason B Fleming
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

6.  Editorial: Special Section on Multiscale Cancer Modeling.

Authors:  Zhihui Wang; Philip K Maini
Journal:  IEEE Trans Biomed Eng       Date:  2017-02-22       Impact factor: 4.538

7.  Scatter spectroscopic imaging distinguishes between breast pathologies in tissues relevant to surgical margin assessment.

Authors:  Ashley M Laughney; Venkataramanan Krishnaswamy; Elizabeth J Rizzo; Mary C Schwab; Richard J Barth; Brian W Pogue; Keith D Paulsen; Wendy A Wells
Journal:  Clin Cancer Res       Date:  2012-08-20       Impact factor: 12.531

Review 8.  The role of engineering approaches in analysing cancer invasion and metastasis.

Authors:  Muhammad H Zaman
Journal:  Nat Rev Cancer       Date:  2013-07-18       Impact factor: 60.716

Review 9.  The sick lobe hypothesis, field cancerisation and the new era of precision breast surgery.

Authors:  Mona P Tan; Tibor Tot
Journal:  Gland Surg       Date:  2018-12

10.  Understanding Drug Resistance in Breast Cancer with Mathematical Oncology.

Authors:  Terisse Brocato; Prashant Dogra; Eugene J Koay; Armin Day; Yao-Li Chuang; Zhihui Wang; Vittorio Cristini
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.